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Background
The licensed lopinavir/r paediatric total daily dose is 460
mg/m2 without, and 600 mg/m2 with concurrent
NNRTIs. The 460 mg/m2 dose without NNRTIs was cho-
sen in preference to 600 mg/m2 in a post-hoc drug-inter-
action analysis [1]. Excellent VL suppression was also
reported (79% <400 c/ml at 48 wks) but was based on the
higher 600 mg/m2 dose. Thus, some paediatricians prefer
this higher dose regardless of concomitant NNRTI ther-
apy.
Methods
We calculated lopinavir/r doses (mg/m2) prescribed with-
out NNRTIs in the UK/Irish CHIPS cohort from 2000–
2007, every time height/weight was measured. We inves-
tigated predictors of current dose, including sex; VL and
CD4% at the previous visit, current age, CDC stage,
height/weight-for-age, calendar year, formulation, fre-
quency and previous PI using mixed models with random
effects for child and centre. We considered whether cur-
rent lopinavir/r dose predicted the next VL being <400 c/
ml using binomial mixed models.
Summary of results
311/1,336 (25%) children in CHIPS had ever taken lopi-
navir/r without NNRTIs, total 654 child-years. Median age
at lopinavir/r initiation was 9.0 years (IQR 5.1–12.1). 684
doses were recorded in 299/311 children: 52% were
syrup, 38% capsules and 10% tablets, with only 3% once
(rather than twice) daily. Dose/m2 could be estimated
2,748 times in 278 children: few (6%) were >10% below
the 460 mg/m2 target, and few (9%) >10% above the 600
mg/m2 target, with most >410–<530 mg/m2 (46%) or
>530–<660 mg/m2 (39%). In a multivariable model,
doses were 17 mg/m2 [95%CI 0–34] higher in children
who had prior AIDS, 2 mg/m2 [0–3] higher for every
log10 higher VL at the previous visit, 48 mg/m2 [38–58]
higher with capsules/tablets vs. syrups, 22 mg/m2 [4–40]
higher with twice- vs. once-daily dosing, 19 mg/m2 [15–
24] and 10 mg/m2 [6–14] higher for every one unit lower
current weight- and height-for-age, respectively, and 9
mg/m2 [5–14] higher for every year younger under 10 (p
< 0.05). Dosing varied widely by centre. Adjusting for age,
there was no strong evidence that higher doses increased
the chance of the next VL being <400 c/ml (OR = 1.10
[0.96–1.25] per 50 mg/m2 higher, p = 0.16) or <50 c/ml
(OR = 0.82 [0.73–0.91], p < 0.001).
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In summary, younger or stunted/wasted children or those
with prior AIDS/higher VLs received higher doses. Doses
were higher with capsules/tablets, likely reflecting over-
rather than under-dosing when solid formulations cannot
achieve exact doses. However, we found no clear evidence
that higher doses improved VL suppression.
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